Adage Capital Partners
ALGS icon

Adage Capital Partners’s Aligos Therapeutics ALGS Stock Holding History

Adage Capital Partners’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-140,000
Closed -$1.37M – 916
2025
Q3 		$1.37M Hold
140,000
– – ﹤0.01% 828
2025
Q2 		$1.01M Sell
140,000
-325,000
-70% -$1.95M ﹤0.01% 793
2025
Q1 		$3.84M Buy
465,000
+140,000
+43% +$3.07M 0.01% 725
2024
Q4 		$12.9M Buy
325,000
+106,187
+49% +$2.05M 0.02% 545
2024
Q3 		$1.89M Buy
218,813
+18,813
+9% +$234K ﹤0.01% 785
2024
Q2 		$1.75M Buy
200,000
+101,420
+103% +$1.78M ﹤0.01% 785
2024
Q1 		$2.42M Buy
+98,580
New +$1.96M ﹤0.01% 767
2023
Q4 		– Sell
-48,931
Closed -$914K – 849
2023
Q3 		$914K Hold
48,931
– – ﹤0.01% 767
2023
Q2 		$1.19M Hold
48,931
– – ﹤0.01% 762
2023
Q1 		$1.07M Sell
48,931
-10,000
-17% -$382K ﹤0.01% 794
2022
Q4 		$1.4M Hold
58,931
– – ﹤0.01% 828
2022
Q3 		$1.62M Hold
58,931
– – ﹤0.01% 869
2022
Q2 		$1.78M Hold
58,931
– – ﹤0.01% 888
2022
Q1 		$3.17M Buy
+58,931
New +$4.72M 0.01% 871

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Adage Capital Partners's ALGS Position: Q4 2025 in Review

Adage Capital Partners sold out of Aligos Therapeutics (ALGS) in Q4 2025, closing a stake of 140,000 shares — an estimated $1.37M sold.

Adage Capital Partners first reported a position in ALGS in Q1 2022 and held it in 14 quarters. The position peaked at $12.9M in Q4 2024. 40 funds tracked by Wall St. Rank hold ALGS as of Q4 2025.

  • Adage Capital Partners reported no remaining Aligos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Adage Capital Partners sold 140,000 Aligos Therapeutics shares in Q4 2025, an estimated $1.37M.
  • Adage Capital Partners first reported a position in Aligos Therapeutics in Q1 2022 and held it in 14 quarters.
  • Adage Capital Partners's Aligos Therapeutics position peaked at $12.9M in Q4 2024.
  • 40 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.